Literature DB >> 1722323

Spectrum of mutations in aspartylglucosaminuria.

E Ikonen1, P Aula, K Grön, O Tollersrud, R Halila, T Manninen, A C Syvänen, L Peltonen.   

Abstract

Aspartylglucosaminuria (AGU) is an inherited lysosomal storage disorder caused by the deficiency of aspartylglucosaminidase. We have earlier reported a single missense mutation (Cys163----Ser) to be responsible for 98% of the AGU alleles in the isolated Finnish population, which contains about 90% of the reported AGU patients. Here we describe the spectrum of 10 AGU mutations found in unrelated patients of non-Finnish origin. Since 11 out of 12 AGU patients were homozygotes, consanguinity has to be a common denominator in most AGU families. The mutations were distributed over the entire coding region of the aspartylglucosaminidase cDNA, except in the carboxyl-terminal 17-kDa subunit in which they were clustered within a 46-amino acid region. Based on the character of the mutations, most of them are prone to affect the folding and stability and not to directly affect the active site of the aspartylglucosaminidase enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722323      PMCID: PMC53106          DOI: 10.1073/pnas.88.24.11222

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Human leucocyte aspartylglucosaminidase. Evidence for two different subunits in a more complex native structure.

Authors:  R Halila; M Baumann; E Ikonen; N Enomaa; L Peltonen
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

2.  Aspartylglycosaminuria. An inborn error of metabolism associated with mental defect.

Authors:  R J Pollitt; F A Jenner; H Merskey
Journal:  Lancet       Date:  1968-08-03       Impact factor: 79.321

3.  Letter: Aspartylglycosaminuria in Northern Norway.

Authors:  O Borud; K H Torp
Journal:  Lancet       Date:  1976-05-15       Impact factor: 79.321

4.  Enzymatic cleavage of glycopeptides.

Authors:  M Makino; T Kojima; I Yamashina
Journal:  Biochem Biophys Res Commun       Date:  1966-09-22       Impact factor: 3.575

5.  Aspartylglycosaminuria in the Finnish population: identification of two point mutations in the heavy chain of glycoasparaginase.

Authors:  I Mononen; N Heisterkamp; V Kaartinen; J C Williams; J R Yates; P R Griffin; L E Hood; J Groffen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  Glycosaparaginase from human leukocytes. Inactivation and covalent modification with diazo-oxonorvaline.

Authors:  V Kaartinen; J C Williams; J Tomich; J R Yates; L E Hood; I Mononen
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

7.  Aspartylglucosaminuria: psychomotor retardation masquerading as a mucopolysaccharidosis.

Authors:  J N Isenberg; H L Sharp
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

8.  Characterization of the mutation responsible for aspartylglucosaminuria in three Finnish patients. Amino acid substitution Cys163----Ser abolishes the activity of lysosomal glycosylasparaginase and its conversion into subunits.

Authors:  K J Fisher; N N Aronson
Journal:  J Biol Chem       Date:  1991-06-25       Impact factor: 5.157

9.  In vitro mutagenesis helps to unravel the biological consequences of aspartylglucosaminuria mutation.

Authors:  E Ikonen; N Enomaa; I Ulmanen; L Peltonen
Journal:  Genomics       Date:  1991-09       Impact factor: 5.736

10.  Aspartylglucosaminuria: cDNA encoding human aspartylglucosaminidase and the missense mutation causing the disease.

Authors:  E Ikonen; M Baumann; K Grön; A C Syvänen; N Enomaa; R Halila; P Aula; L Peltonen
Journal:  EMBO J       Date:  1991-01       Impact factor: 11.598

View more
  18 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Sleep disturbances in aspartylglucosaminuria (AGU): a questionnaire study.

Authors:  Niki Lindblom; Satu Kivinen; Hannu Heiskala; Maija-Liisa Laakso; Markus Kaski
Journal:  J Inherit Metab Dis       Date:  2006-08-30       Impact factor: 4.982

3.  The age of human mutation: genealogical and linkage disequilibrium analysis of the CLN5 mutation in the Finnish population.

Authors:  T Varilo; M Savukoski; R Norio; P Santavuori; L Peltonen; I Järvelä
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

4.  Triple primer polymerase chain reaction. A new way to quantify truncated mRNA expression.

Authors:  E Leygue; L Murphy; F Kuttenn; P Watson
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

5.  Assignment of the locus for PLO-SL, a frontal-lobe dementia with bone cysts, to 19q13.

Authors:  P Pekkarinen; I Hovatta; P Hakola; O Järvi; M Kestilä; U Lenkkeri; R Adolfsson; G Holmgren; P O Nylander; L Tranebjaerg; J D Terwilliger; J Lönnqvist; L Peltonen
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

6.  Overgrowth of oral mucosa and facial skin, a novel feature of aspartylglucosaminuria.

Authors:  P Arvio; M Arvio; M Kero; S Pirinen; P L Lukinmaa
Journal:  J Med Genet       Date:  1999-05       Impact factor: 6.318

7.  Structural constraints on autoprocessing of the human nucleoporin Nup98.

Authors:  Yixin Sun; Hwai-Chen Guo
Journal:  Protein Sci       Date:  2008-03       Impact factor: 6.725

8.  Single base deletion in exon 7 of the glycosylasparaginase gene causes a mild form of aspartylglycosaminuria in a patient of Mauritian origin.

Authors:  H Park; M Rossiter; A H Fensom; B Winchester; N N Aronson
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

9.  Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns.

Authors:  Arthur Arcinas; Ten-Yang Yen; Electron Kebebew; Bruce A Macher
Journal:  J Proteome Res       Date:  2009-08       Impact factor: 4.466

10.  Characterization of three alleles causing aspartylglycosaminuria: two from a British family and one from an American patient.

Authors:  H Park; M B Vettese; A H Fensom; K J Fisher; N N Aronson
Journal:  Biochem J       Date:  1993-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.